The Flinn Foundation Seed Grants to Promote Translational Research Program application will open August 1, 2024.

Two scientists review brain scans of a radiotherapy patient.

Application Requirements

Proposed projects for the Flinn Foundation Seed Grants to Promote Translational Research Program must address compelling clinical needs in the areas of precision medicine, diagnostics, devices, therapeutics, or health-care-delivery processes—and have significant potential to turn bench results into viable products or systems impacting patients in Arizona and beyond.

The application requires:

  • a letter of support from the vice president of research or their designee at the principal investigator’s institution;
  • a 300-word project summary; and
  • a slide deck with required elements.

The principal investigator must have, or be working with their institution on, an agreed path for licensing or ownership of the project’s IP.

Proposals will be evaluated by an independent review committee of academic and industry experts appointed by the Flinn Foundation. Constructive feedback will be offered to all applicants.

Key Dates

August 1, 2024: Application opens
August 8, 2024: Virtual information session (12-1 p.m.)
August 22, 2024: Virtual office hours (2-3 p.m.)
September 19, 2024: Virtual office hours (12-1 p.m.)
September 26, 2024: Application deadline
Mid-December 2024: Awardees notified

Program eligibility

For a research team to be eligible for the program:

  • The principal investigator must be employed by an Arizona-based, nonprofit academic- or medical- research institution or health system;
  • The proposed product and/or process must address a clearly defined, compelling clinical need; and
  • The project team must have a blend of skills (e.g., scientific, clinical, engineering, business, regulatory) to meet the proposal goals.
  • The principal investigator must agree to participate in grant programming provided by the Flinn Foundation.
  • Previous Flinn Foundation grantees may apply as a principal investigator if all previous Flinn grants are closed.

“This grant helped us pursue our passion: developing solutions for unmet needs of people with Type 1 diabetes. The award enabled us to test our ideas at the bedside, then at the bench—with the aim to translate them back soon.”

Sampathkumar Rangasamy, Ph.D., Principal Investigator
Translational Genomics Research Institute in partnership with Mayo Clinic: “An innovative application for diabetes personalized care


For more information about the program or to learn about future application opportunities, contact Mary O’Reilly, Ph.D., Flinn Foundation Vice President, Bioscience Research Programs.